MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that the previously announced product license agreement under which Solvay Pharmaceuticals will have exclusive rights for DM-1796 for the treatment of pain in the United States, Canada, Mexico and Puerto Rico, has cleared review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. The $25 million upfront payment to Depomed under the agreement is due 60 days following today’s completion of the HSR review.
